Document:

<Page>

                       MORGAN STANLEY SELECT EQUITY TRUST
            MORGAN STANLEY HIGH-TECHNOLOGY 35 INDEX PORTFOLIO 2001-4
                            REFERENCE TRUST AGREEMENT

     This Reference Trust Agreement dated September 25, 2001 between MORGAN
STANLEY DW INC., as Depositor, and The Bank of New York, as Trustee, sets forth
certain provisions in full and incorporates other provisions by reference to the
document entitled "Morgan Stanley Dean Witter Select Equity Trust, Trust
Indenture and Agreement" (the "Basic Agreement") dated September 30, 1993 as
amended on December 30, 1997. Such provisions as are incorporated by reference
constitute a single instrument (the "Indenture").

                                WITNESSETH THAT:

     In consideration of the premises and of the mutual agreements herein
contained, the Depositor and the Trustee agree as follows:

                                       I.

                     STANDARD TERMS AND CONDITIONS OF TRUST

     Subject to the provisions of Part II hereof, all the provisions contained
in the Basic Agreement are herein incorporated by reference in their entirety
and shall be deemed to be a part of this instrument as fully and to the same
extent as though said provisions had been set forth in full in this instrument
except that the Basic Agreement is hereby amended as follows:

          A. The first sentence of Section 2.01 is amended to add the following
     language at the end of such sentence: "and/or cash (or a letter of credit
     in lieu of cash) with instructions to the Trustee to purchase one or more
     of such Securities which cash (or cash in an amount equal to the face
     amount of the letter of credit), to the extent not used by the Trustee to
     purchase such Securities within the 90-day period following the first
     deposit of Securities in the Trust, shall be distributed to Unit Holders on
     the Distribution Date next following such 90-day period or such earlier
     date as the Depositor and the Trustee determine".

<Page>

                                      -2-

          B. Section 2.03 is amended to add the following to the end of the
     first paragraph thereof. The number of Units may be increased through a
     split of the Units of decreased through a reverse split thereof, as
     directed by the Depositor, which revised number of Units shall be recorded
     by Trustee on its books.

          C. The first sentence of Section 2.06 is amended to add the following
     language after "Securities"))": "and/or cash (or a letter of credit in lieu
     of cash) with instructions to the Trustee to purchase one or more
     Additional Securities which cash (or cash in an amount equal to the face
     amount of the letter of credit), to the extent not used by the Trustee to
     purchase such Additional Securities within the 90-day period following the
     first deposit of Securities in the Trust, shall be distributed to Unit
     Holders on the Distribution Date next following such 90-day period or such
     earlier date as the Depositor and the Trustee determine".

          D. Article III, entitled "Administration of Trust", Section 3.01
     Initial Cost shall be amended as follows:

     Section 3.01 Initial Cost shall be amended to substitute the following
language:

          SECTION 3.01. INITIAL COST The costs of organizing the Trust and sale
     of the Trust Units shall, to the extent of the expenses reimbursable to the
     Depositor provided below, be borne by the Unit Holders, PROVIDED, HOWEVER,
     that, to the extent all of such costs are not borne by Unit Holders, the
     amount of such costs not borne by Unit Holders shall be borne by the
     Depositor and, PROVIDED FURTHER, HOWEVER, that the liability on the part of
     the Depositor under this section shall not include any fees or other
     expenses incurred in connection with the administration of the Trust
     subsequent to the deposit referred to in Section 2.01. Upon notification
     from the Depositor that the primary offering period is concluded, the
     Trustee shall withdraw from the Account or Accounts specified in the
     Prospectus or, if no Account is therein specified, from the Principal
     Account, and pay to the Depositor the Depositor's reimbursable expenses of
     organizing the Trust and sale of the Trust Units in an amount certified to
     the Trustee by the Depositor. If the balance of the Principal Account is
     insufficient to make such withdrawal, the Trustee shall, as di-

<Page>
                                      -3-

     rected by the Depositor, sell Securities identified by the Depositor, or
     distribute to the Depositor Securities having a value, as determined under
     Section 4.01 as of the date of distribution, sufficient for such
     reimbursement. The reimbursement provided for in this section shall be for
     the account of the Unitholders of record at the conclusion of the primary
     offering period and shall not be reflected in the computation of the Unit
     Value prior thereto. As used herein, the Depositor's reimbursable expenses
     of organizing the Trust and sale of the Trust Units shall include the cost
     of the initial preparation and typesetting of the registration statement,
     prospectuses (including preliminary prospectuses), the indenture, and other
     documents relating to the Trust, SEC and state blue sky registration fees,
     the cost of the initial valuation of the portfolio and audit of the Trust,
     the initial fees and expenses of the Trustee, and legal and other
     out-of-pocket expenses related thereto, but not including the expenses
     incurred in the printing of preliminary prospectuses and prospectuses,
     expenses incurred in the preparation and printing of brochures and other
     advertising materials and any other selling expenses. Any cash which the
     Depositor has identified as to be used for reimbursement of expenses
     pursuant to this Section shall be reserved by the Trustee for such purpose
     and shall not be subject to distribution or, unless the Depositor otherwise
     directs, used for payment of redemptions in excess of the per-Unit amount
     allocable to Units tendered for redemption.

          E. The third paragraph of Section 3.05 is hereby amended to add the
     following sentence after the first sentence thereof: "Depositor may direct
     the Trustee to invest the proceeds of any sale of Securities not required
     for the redemption of Units in eligible money market instruments selected
     by the Depositor which will include only negotiable certificates of deposit
     or time deposits of domestic banks which are members of the Federal Deposit
     Insurance Corporation and which have, together with their branches or
     subsidiaries, more than $2 billion in total assets, except that
     certificates of deposit or time deposits of smaller domestic banks may be
     held provided the deposit does not exceed the insurance coverage on the
     instrument (which currently is $100,000), and provided further that the
     Trust's aggregate holding of certificates of deposit or time deposits
     issued by the Trustee may not ex-

<Page>

                                      -4-

     ceed the insurance coverage of such obligations and U.S. Treasury notes
     or bills (which shall be held until the maturity thereof) each of which
     matures prior to the earlier of the next following Distribution Date or 90
     days after receipt, the principal thereof and interest thereon (to the
     extent such interest is not used to pay Trust expenses) to be distributed
     on the earlier of the 90th day after receipt or the next following
     Distribution Date."

          F. The first sentence of each of Sections 3.10, 3.11 and 3.12 is
     amended to insert the following language at the beginning of such sentence,
     "Except as otherwise provided in Section 3.13,".

          G. The following new Section 3.13 is added

          Section 3.13. EXTRAORDINARY EVENT-SECURITY RETENTION AND VOTING. In
     the event the Trustee is notified of any action to be taken or proposed to
     be taken by holders of the securities held by the Trust in connection with
     any proposed merger, reorganization, spin-off, split-off or split-up by the
     issuer of stock or securities held in the Trust, the Trustee shall take
     such action or refrain from taking any action, as appropriate, so as to
     insure that the securities are voted as closely as possible in the same
     manner and in the same general proportion as are the securities held by
     owners other than the Trust. If stock or securities are received by the
     Trustee, with or without cash, as a result of any merger, reorganization,
     spin-off, split-off or split-up by the issuer of stock or securities held
     in the Trust, the Trustee at the direction of the Depositor may retain such
     stock or securities in the Trust. Neither the Depositor nor the Trustee
     shall be liable to any person for any action or failure to take action with
     respect to this section.

          H. Section 1.01 is amended to add the following definition: (9)
     "Deferred Sales Charge" shall mean any deferred sales charge payable in
     accordance with the provisions of Section 3.14 hereof, as set forth in the
     prospectus for a Trust. Definitions following this definition (9) shall be
     renumbered.

          I. Section 3.05 is hereby amended to add the following paragraph after
     the end thereof: On each Deferred Sales Charge payment date set forth in
     the prospectus for

<Page>

                                      -5-

     a Trust, the Trustee shall pay the account created pursuant to Section 3.14
     the amount of the Deferred Sales Charge payable on each such date as stated
     in the prospectus for a Trust. Such amount shall be withdrawn from the
     Principal Account from the amounts therein designated for such purpose.

          J. Section 3.06B(3) shall be amended by adding the following: "and any
     Deferred Sales Charge paid".

          K. Section 3.08 shall be amended by adding the following at the end
     thereof: "In order to pay the Deferred Sales Charge, the Trustee shall sell
     or liquidate an amount of Securities at such time and from time to time and
     in such manner as the Depositor shall direct such that the proceeds of such
     sale or liquidation shall equal the amount required to be paid to the
     Depositor pursuant to the Deferred Sales Charge program as set forth in the
     prospectus for a Trust.

          L. Section 3.14 shall be added as follows:
          Section 3.14. Deferred Sales Charge. If the prospectus for a Trust
     specifies a Deferred Sales Charge, the Trustee shall, on the dates
     specified in and as permitted by the prospectus, withdraw from the Income
     Account if such account is designated in the prospectus as the source of
     the payments of the Deferred Sales Charge, or to the extent funds are not
     available in that account or if such account is not so designated, from the
     Principal Account, an amount per Unit specified in the prospectus and
     credit such amount to a special, non-Trust account maintained at the
     Trustee out of which the Deferred Sales Charge will be distributed to the
     Depositor. If the Income Account is not designated as the source of the
     Deferred Sales Charge payment or if the balances in the Income and
     Principal Accounts are insufficient to make any such withdrawal, the
     Trustee shall, as directed by the Depositor, either advance funds, if so
     agreed to by the Trustee, in an amount equal to the proposed withdrawal and
     be entitled to reimbursement of such advance upon the deposit of additional
     monies in the Income Account or the Principal Account, sell Securities and
     credit the proceeds thereof to such special Depositor's account or credit
     Securities in kind to such special Depositor's Account. Such directions
     shall identify the Securities, if any, to be

<Page>

                                      -6-

     sold or distributed in kind and shall contain, if the Trustee is directed
     by the Depositor to sell a Security, instructions as to execution of such
     sales. If a Unit Holder redeems Units prior to full payment of the Deferred
     Sales Charge, the Trustee shall, if so provided in the prospectus, on the
     Redemption Date, withhold from the Redemption Price payment to such Unit
     Holder an amount equal to the unpaid portion of the Deferred Sales Charge
     and distribute such amount to such special Depositor's account or, if the
     Depositor shall purchase such Unit pursuant to the terms of Section 5.02
     hereof, the Depositor shall pay the Redemption Price for such Unit less the
     unpaid portion of the Deferred Sales Charge. The Depositor may at any time
     instruct the Trustee to distribute to the Depositor cash or Securities
     previously credited to the special Depositor's account.

          M. Reference to "Morgan Stanley Dean Witter Select Equity Trust" is
     replaced by "Morgan Stanley Select Equity Trust".

          N. Reference to "Dean Witter Reynolds Inc." is replaced by "Morgan
     Stanley DW Inc."

          O. Section 2.03 is amended to add the following to the end of
     the first paragraph thereof. The number of Units may be increased through a
     split of the Units of decreased through a reverse split thereof, as
     directed by the Depositor, which revised number of Units shall be recorded
     by Trustee on its books.

                                      II.

                      SPECIAL TERMS AND CONDITIONS OF TRUST

     The following special terms and conditions are hereby agreed to:

     A. The Trust is denominated Morgan Stanley Select Equity Trust Morgan
Stanley High-Technology 35 Index Portfolio 2001-4 (the "High-Tech Trust").

     B. The publicly traded stocks listed in Schedule A hereto are those which,
subject to the terms of this Indenture, have been or are to be deposited in
trust under this Indenture.

<Page>

                                      -7-

     C. The term, "Depositor" shall mean Morgan Stanley DW Inc.

     D. The aggregate number of Units referred to in Sections 2.03 and 9.01 of
the Basic Agreement is 25,041 for the High-Tech Trust.

     E. A Unit is hereby declared initially equal to 1/25,041th for the
High-Tech Trust.

     F. The term "In-Kind Distribution Date" shall mean November 25, 2002.

     G. The term "Record Dates" shall mean May 1, 2002, and December 23, 2002
and such other date as the Depositor may direct.

     H. The term "Distribution Dates shall mean May 15, 2002 and on or about
December 30, 2002 and such other date as the Depositor may direct.

     I. The term "Termination Date" shall mean December 23, 2002.

     J. The Depositor's Annual Portfolio Supervision Fee shall be a maximum of
$0.25 per 100 Units.

     K. The Trustee's Annual Fee as defined in Section 6.04 of the Indenture
shall be $0.72 per 100 Units.

     L. For a Unit Holder to receive an "in-kind" distribution during the life
of the Trust, such Unit Holder must tender at least 25,000 Units for redemption.
There is no minimum amount of Units that a Unit Holder must tender in order to
receive an "in-kind" distribution on the In-Kind Date or in connection with a
rollover.

     M. The Indenture is amended to provide that the period during which the
Trustee shall liquidate the Trust Securities shall not exceed 20 business days
commencing on the first business day following the In-Kind Date.

               (Signatures and acknowledgments on separate pages)

<Page>

                                      -8-

     The Schedule of Portfolio Securities in the prospectus included in this
Registration Statement is hereby incorporated by reference herein as Schedule A
hereto.<PAGE>

                                                                    Exhibit 10.1

                           WORLDWIDE LICENSE AGREEMENT

This WORLDWIDE LICENSE AGREEMENT (this "License Agreement"), effective as of
September 25, 2001 (the "Effective Date"), is between BRACCO IMAGING S.P.A., an
Italian corporation having a principal place of business at Via Egidio Folli, n.
50, 20134 Milan ("Bracco"), on one side; and EPIX MEDICAL, INC., a Delaware
corporation, having a principal place of business at 71 Rogers Street,
Cambridge, MA 02142, USA ("EPIX"), on the other side. Bracco and EPIX may be
referred to separately as a "Party" or collectively as the "Parties."

                                    RECITALS

         WHEREAS, EPIX has certain rights under certain patents and patent
applications owned by The General Hospital Corporation, doing business as
Massachusetts General Hospital ("GH"), pursuant to an Amended and Restated
License Agreement dated July 10, 1995, as amended, between EPIX and GH;

         WHEREAS, Bracco possesses certain rights relating to Licensed
Product(s) (defined below);

         WHEREAS, the Parties are involved in several disputes now pending
before European and Japanese authorities with respect to Licensed Products and
Licensed Patents (defined below);

         WHEREAS, the Parties have agreed to resolve the several disputes now
pending before European and Japanese authorities as more fully set forth in a
Settlement and Release Agreement dated September 25, 2001;

         WHEREAS, EPIX is willing to grant Bracco a worldwide nonexclusive
sublicense under the Licensed Patents and a worldwide nonexclusive license under
the EPIX Patents (defined below); and

         WHEREAS, Bracco is willing to accept from EPIX a worldwide nonexclusive
sublicense under the Licensed Patents and a worldwide nonexclusive license under
the EPIX Patents.

         NOW THEREFORE, in consideration of the foregoing and the covenants and
promises contained in this License Agreement, the Parties hereto hereby agree as
follows:

                                    ARTICLE 1

                                   DEFINITIONS

         For purposes of this License Agreement, the terms defined in this
Article shall have the meanings specified below. These terms are intended to
encompass both the singular and plural forms.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

<PAGE>

         1.1 "AFFILIATE" shall mean a corporation or other legal entity that
controls, is controlled by, or is under common control with a Party to this
License Agreement. For purposes of this definition, "control" means the
ownership, directly or indirectly, of more than fifty percent (50%) of the
outstanding equity securities of a corporation which are entitled to vote in the
election of directors or more than fifty percent (50%) interest in the net
assets or profits of an entity which is not a corporation. For the purposes of
this definition, Bracco Affiliates shall include those Affiliates that are, or
will become, Sublicensees of this Worldwide License Agreement and shall
initially include the entities identified on Exhibit 1 and any future similarly
organized Bracco Affiliates.

         1.2 "BRACCO" shall mean Bracco identified as a Party above.

         1.3 "BRACCO NET SALES" shall mean the amounts invoiced or otherwise
charged on the sales of Licensed Products by Bracco or its Affiliates to
Unaffiliated Third Parties in bona fide arms' length transactions: less (a)
trade, cash and quantity discounts, including charge backs, rebates, premiums,
allowances and any other deduction actually granted to the Unaffiliated Third
Parties; (b) sales and excise taxes and duties and any other governmental
charges imposed upon the importation, use or sale of the Licensed Products
actually charged to the Unaffiliated Third Parties; (c) freight, insurance and
other transportation charges actually charged to the Unaffiliated Third Parties;
(d) amounts repaid or credited by reason of rejections, defects, outdating,
price differences, recalls or returns, or because of retroactive price
reductions, or due to governmental laws or regulations requiring rebates
actually granted to the Unaffiliated Third Parties; and (e) a three percent (3%)
flat deduction to cover other expenses and deductions not otherwise accounted
for. Except pursuant to 1.3(e), any and all deductions used in the calculations
of Bracco Net Sales are allowable only to the extent that they have already been
included in the amounts invoiced or otherwise charged or granted on the sales of
Licensed Products by Bracco or its Affiliates to Unaffiliated Third Parties in
bona fide arms' length transactions. Calculations of Bracco Net Sales shall be
in accordance with generally accepted accounting standards of the countries in
which the Licensed Products are sold. No deductions of any kind whatsoever shall
be made in respect of sales of Licensed Products made prior to January 1, 2001,
as the royalties in respect of such sales have been determined solely in
accordance with Section 2.4(a) hereof.

         1.4 "EPIX" shall mean EPIX identified as a Party above and any EPIX
Affiliate.

         1.5 "EPIX PATENTS" shall mean any and all patents and patent
applications covering the Licensed Products, other than the Licensed Patents,
that are currently or may hereafter be owned, obtained, acquired, purchased by
or licensed to, with a right to sublicense, or in any way under the control or
at the disposal of EPIX, including any division, renewal, continuation,
continuation-in-part, extension, reissue, reexamination, substitution,
confirmation, registration, revalidation, supplementary protection certificate
or any extension or additions thereto.

         1.6 "FDA APPROVAL" shall mean that a Licensed Product has been approved
for immediate nationwide sale by the U.S. Food and Drug Administration.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -2-
<PAGE>

         1.7 "LICENSED PATENTS" shall mean all patents and patent applications
owned by GH listed on Exhibit 2 of this License Agreement and licensed to EPIX,
including any division, renewal, continuation, continuation-in-part, extension,
reissue, reexamination, substitution, confirmation, registration, revalidation,
supplementary protection certificate or any extension or additions thereto.

         1.8 "LICENSED PRODUCTS" shall mean any pharmaceutical product or
formulation sold by Bracco or its Affiliates comprising the drug substance
having the chemical name (4-carboxy-5, 8, 11-tris
(carboxymethyl)-1-phenyl-2-oxa-5, 8, 11-triazatridecan-13-oato (5-)) gadolinate
(2-) dihydrogen, including but not limited to the product identified by Bracco's
trademark "MultiHance" and having the CAS Registry Number 127000-20-8; and
intermediates used in making, methods of preparing and methods of using such
product or formulation, that, absent the license provided in this License
Agreement, would be an infringement of a Valid Claim of the Licensed Patents.

         1.9 "NAMED ENTITIES" shall mean those entities involved in the
actions/disputes described in Exhibit 4 of the S/R Agreement, excluding EPIX and
GH.

         1.10 "PRIME RATE" shall mean the prime rate of interest as published in
the Wall Street Journal on the first business day of each calendar quarter.

         1.11 "S/R AGREEMENT" shall mean the Settlement and Release Agreement
entered into by EPIX, Bracco and GH on September 25, 2001.

         1.12 "SUBLICENSEE" shall mean an Affiliate of Bracco who obtains a
sublicense under the Licensed Patents pursuant to Section 2.2 of this License
Agreement.

         1.13 "TERRITORY" shall mean any country in the world in which a
Licensed Patent has issued and a Valid Claim is in effect. Exhibit 5 lists the
countries in which a Licensed Patent has issued with reference to the time of
execution of this Agreement.

         1.14 "THIRD PARTIES" shall mean any entities other than EPIX, Bracco
or a Bracco Affiliate.

         1.15 "UNAFFILIATED THIRD PARTIES" shall mean any Third Party and shall
include without limitation the joint venture partner, company or other entity
that also has non-controlling outstanding equity securities of a Bracco
Affiliate or has a non-controlling interest in the net assets or profits of an
entity which is a Bracco Affiliate, such as Eisai Ltd. Co. or Byk Gulden Lomberg
Chemische Fabrik, GmbH or is a parent or affiliate of such entity.

         1.16 "VALID CLAIM" shall mean a claim in an issued, unexpired Licensed
Patent as so provided for by this License Agreement, that, absent the license
provided in this License Agreement, would be infringed by the Licensed Products,
that (i) has not been finally cancelled, withdrawn, abandoned or rejected by any
administrative agency or other body of competent jurisdiction, (ii) has not been
revoked, held invalid, or declared unpatentable or unenforceable in

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -3-
<PAGE>

a decision of a court or other body of competent jurisdiction that is
unappealable or unappealed within the time allowed for appeal, (iii) has not
been rendered unenforceable through disclaimer or otherwise, or (iv) is not lost
through an interference proceeding.

         1.17 "LICENSE AGREEMENT" shall mean this Worldwide License Agreement
between Bracco and EPIX, as of its Effective Date.

                                   ARTICLE 2

   WORLDWIDE NONEXCLUSIVE SUBLICENSE UNDER THE LICENSED PATENTS AND WORLDWIDE
                   NONEXCLUSIVE LICENSE UNDER THE EPIX PATENTS

         2.1 GRANT OF LICENSE. EPIX hereby grants to Bracco, and Bracco hereby
accepts, a worldwide nonexclusive sublicense under the Licensed Patents and a
worldwide nonexclusive license under the EPIX Patents to conduct research and to
develop, use, make, have made, import or export, manufacture, have manufactured,
offer for sale, sell and/or have sold, advertise and promote the Licensed
Products in the Territory. It is agreed and understood that decisions regarding
such activities will be made by Bracco at its sole discretion. Bracco has
received approval for marketing Licensed Products in the Territory in the
countries of Austria, Belgium, France, Germany, Italy, Luxembourg, Sweden, The
Netherlands and the United Kingdom, and shall provide written notice to EPIX
within thirty (30) days from the approval date if and when Licensed Products are
approved for marketing in any other country in the Territory.

         2.2 SUBLICENSES. Bracco shall have the limited right to grant
sublicenses under the Licensed Patents and the EPIX Patents as set forth in
Section 2.1 hereof solely to Bracco's Affiliates. Bracco has listed its current
Sublicensees on Exhibit 1 and shall provide EPIX with an updated list quarterly
of the names and addresses of all newly appointed Sublicensees.

         2.3 UPFRONT AND LICENSE FEES. In consideration for the sublicense
granted in Section 2.1 and the right to grant sublicenses granted in Section 2.2
hereof, Bracco shall pay EPIX within thirty (30) days following the execution of
this License Agreement, but in no event later than September 27, 2001:

         (a) a non-refundable license fee of $2,000,000;

         (b) a fee of $3,000,000 as an advance payment for MultiHance FDA
Approval Milestone Payment subject to Section 2.5;

         (c) a fee of $3,000,000 that is an advance payment to be treated as a
credit against the Threshold royalty payments pursuant to Section 2.4(b); and

         (d) a fee of $1,000,000 that is an advance payment against future
royalty payments subject to Section 2.4(c).

         2.4 ROYALTIES AND CREDIT AGAINST FUTURE ROYALTY PAYMENTS. In further
consideration of the license granted in Sections 2.1 and 2.2 hereof, Bracco
shall pay EPIX:

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -4-
<PAGE>

         (a) $1,000,000 within thirty (30) days following the execution of this
License Agreement, but in no event later than September 27, 2001, as full,
non-refundable payment for royalties due on Bracco Net Sales prior to January 1,
2001;

         (b) for the Licensed Products sold by Bracco or a Bracco Affiliate to
an Unaffiliated Third Party in the Territory that are covered by a Valid Claim
in such Territory (only one royalty shall be payable for each Licensed Product
irrespective of the number of Valid Claims in each country and payment of such
royalty for each Licensed Product shall end all further royalty obligations
therefor including, without limitation, any obligation of distributors or
customers of Bracco or its Affiliates), a royalty in an amount equal to:

                  (i)      [ * ] of Bracco Net Sales for the first [ * ]
                           (hereinafter the "Threshold") of Bracco Net Sales
                           made on or after January 1, 2001, but, as a
                           consequence of the credit against future royalties
                           provided for in Section 2.3 (c), the actual royalty
                           to be paid shall be [ * ] of Bracco Net Sales until
                           the achievement of the Threshold, calculated as
                           follows:

                           Threshold Royalty Obligation: [ * ] x [ * ] = [ * ]

                           Less Pre-Payments: [ * ] - [ * ] = [ * ]

                           Threshold Calculated Royalty after Pre-Payments:
                           [ * ]:

                           Calculated Threshold Royalty Rate = [ * ] / [ * ] =
                           [ * ] [ * ]

                  (ii)     [ * ] of Bracco Net Sales in excess of the Threshold.

         Except as otherwise provided for in this License Agreement, it is,
however, agreed and understood that royalties on Bracco Net Sales in any country
as provided for in this Section 2.4 shall be due to EPIX until the date of
expiration in such country of the last to expire Valid Claim of the Licensed
Patents covering the Licensed Products, with no royalties due thereafter on such
Bracco Net Sales.

         (c) Beginning on the date following receipt by EPIX of the funds set
forth in Section 2.3(d) ($1,000,000) and continuing until December 31, 2004,
Bracco shall be granted a quarterly credit to royalties due pursuant to Section
2.4(b) equal to the amount set forth in Section 2.3(d) ($1,000,000) multiplied
by the Prime Rate plus [ * ] multiplied by the number of days such funds were
outstanding during the quarter divided by the total number of days in a year
(365).

                  EXAMPLE: $1,000,000 IS OUTSTANDING FOR THE THIRD QUARTER AND
                  PRIME RATE IS 7%

                  Calculation: ($1,000,000 x [ * ]) x (92/365) = [ * ] royalty
                  credit

In the event that the royalty credit calculated herein exceeds the actual
royalty due pursuant to Section 2.4(b), such excess shall be carried forward to
the next quarterly period and applied to

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -5-
<PAGE>

such future royalty due. In the event that an excess of such royalty credit
exists on December 31, 2004, EPIX shall, within ten (10) days after receipt of
the information from Bracco as set forth in Section 2.6, refund such excess to
Bracco.

         (d) Beginning on January 1, 2005, Bracco shall have the right to offset
the amount set forth in Section 2.3 (d) (i.e. $1,000,000) against royalties due
to EPIX pursuant to Section 2.4(b).

         2.5 MULTIHANCE FDA APPROVAL MILESTONE PAYMENT.

         (a) Except as set forth in Section 2.5 (c), in the event that a
Licensed Product receives FDA Approval prior to June 30, 2003, and provided that
upon the receipt of such FDA approval, at least one Valid Claim covering such
approved Licensed Product is in full force and effect in the United States, then
the fee set forth in Section 2.3(b) shall be treated as a non-refundable license
fee as of the date of such FDA approval.

         (b) Except as provided in Section 2.5 (c), in the event that FDA
Approval for a Licensed Product is not obtained prior to June 30, 2003, then
Bracco shall have the right to offset the amount set forth in Section 2.3(b)
(i.e., $3,000,000) against future royalties due pursuant to Section 2.4 (b) as
calculated on Exhibit 3 until either (i) the full offset of the $3,000,000 or
(ii) the date on which FDA Approval for a Licensed Product is received. It is
agreed, however, that, upon the receipt of FDA Approval for a Licensed Product,
provided that at the time of the FDA Approval at least one Valid Claim covering
such approved Licensed Product is in full force and effect in the United States,
then the fee set forth in Section 2.3(b) shall be treated as a non-refundable
license fee as of the date of such FDA Approval. If, at such FDA Approval date,
Bracco has offset any amounts pursuant to Section 2.3(b), then within ten (10)
days of the date such FDA Approval is received, Bracco will pay EPIX an amount
equal to the amount that Bracco has offset from royalties due through the date
of receipt of such FDA Approval pursuant to this Section 2.5(b). In the event
that the $3,000,000 has been offset in full, Bracco will pay EPIX $3,000,000.

         (c) In the event that a decision of a court or other body of competent
jurisdiction determines the unenforceability or invalidity of all the claims of
the Licensed Patents covering the Licensed Products for which FDA Approval is
being sought in the United States prior to the date on which FDA Approval for
such Licensed Product is received, then (i) the payments made pursuant to
Section 2.3(b) shall not be treated as a non-refundable license fee as provided
for in Section 2.5(a) and (ii) Bracco shall be able to continue to take or
commence taking the offsets provided for in Section 2.5(b) until and unless at
least one claim covering the Licensed Products is ultimately reinstated in a
final appeal as a valid and enforceable claim, at which time Bracco's
obligations pursuant to the provisions of Sections 2.5(a) and (b) shall be
reinstated.

         (d) Beginning on the date following receipt by EPIX of the funds set
forth in Section 2.3(b) ($3,000,000) and continuing until the earlier of FDA
Approval of a Licensed Product or June 30, 2003, Bracco shall be granted a
quarterly credit to royalties due pursuant to Section 2.4(b) equal to the amount
set forth in Section 2.3(b) ($3,000,000) multiplied by the Prime Rate

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -6-
<PAGE>

plus [ * ] multiplied by the number of days such funds were outstanding during
the quarter divided by the total number of days in a year (365).

                  EXAMPLE: $3,000,000 IS OUTSTANDING FOR THE THIRD QUARTER AND
                  PRIME RATE IS 7%

                  Calculation: ($3,000,000 x .[ * ]) x (92/365) = [ * ] royalty
                  credit

In the event that the royalty credit calculated herein exceeds the actual
royalty due pursuant to Section 2.4(b), such excess shall not be refundable by
EPIX during such quarter but, instead shall be carried forward to the next
quarterly period and applied to such future royalty due. In the event that an
excess of such royalty credit exists on December 31, 2005, EPIX shall within ten
(10) days of receipt of the information from Bracco as set forth in Section 2.6,
refund such excess to Bracco.

         2.6 STATEMENT AND REMITTANCE. Beginning with the calendar quarter
ending on March 31, 2001 and continuing on a country-by-country basis, until the
last to expire of the Licensed Patents, within sixty (60) days after the end of
each calendar quarter (except with respect to the quarters ended March 31 and
June 30, 2001, for which sums due shall be paid within thirty (30) days of the
execution of this License Agreement, but in no event later than September 27,
2001), Bracco shall send royalty payments to EPIX along with a detailed written
statement of all information relevant to the calculation of Bracco Net Sales and
royalty payments on a country-by-country basis, including the units of Licensed
Products sold and credits made as permitted in the relevant calendar quarter for
which royalties are payable and the amount of royalties due according to Section
2.4 above.

         2.7 PAYMENT IN ESCROW. If a decision of a court or other body of
competent jurisdiction determines the unenforceability or invalidity of all of
the claims of the Licensed Patents in a country in the Territory resulting in
there being no Valid Claims remaining in that country covering the Licensed
Products, then the amount of royalties to be paid to EPIX by Bracco in respect
of Bracco Net Sales in that country pursuant to Section 2.4(b) thereafter will
be put in escrow by Bracco awaiting a final decision by a court from which no
appeal may be taken. In the event that the Threshold has not been achieved, only
the actual royalty of [ * ] will be payable into the escrow account. Any
royalties paid by Bracco to EPIX for any period during which a Valid Claim in a
country is in full force and effect, prior to an adjudication of invalidity or
unenforceability by a court or other body of competent jurisdiction, shall be
nonrefundable

         2.8 RECORDS. Bracco and its Sublicensees shall keep accurate records
with respect to all Licensed Products sold hereunder in sufficient detail to
enable EPIX to determine the amount of royalties that are due and payable
hereunder. Records shall be kept at their principal place of business and be
open during reasonable business hours, for a period of three (3) years from the
end of the calendar year to which such royalties apply, for examination at EPIX'
expense by a certified public accountant selected by EPIX (subject to Bracco's
consent, such consent not to be unreasonably withheld or delayed), for the sole
purpose of verifying the correctness of calculations and classifications of
Bracco Net Sales under this License Agreement. Records per each calendar year
shall be audited only once. EPIX shall bear its own costs related to such

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -7-
<PAGE>

audit; provided, that, for any underpayments greater than five percent (5%) of
annual royalties payable by Bracco, Bracco shall pay EPIX the amount of
underpayment, together with interest at the Prime Rate plus five percent (5%),
as determined in accordance with Section 1.7 above, from the time the amount was
due and EPIX' out-of-pocket expenses related to the audit. For any underpayments
less than five percent (5%) of annual royalties payable found under this
Section, Bracco shall pay EPIX the amount of the underpayment plus interest at
the Prime Rate from the time the amount was due. Any overpayments by Bracco will
be refunded to Bracco or credited to future payments by Bracco to EPIX, at
Bracco's election. Any records or accounting information received from Bracco
shall be Confidential Information of Bracco for purposes of Article 4. Results
of any such audit shall be provided to both Parties and GH, and shall be
Confidential Information of Bracco for purposes of Article 4.

         2.9 TERMS OF PAYMENTS. All payments shall be made in United States
dollars. Conversion of foreign currency to U.S. dollars shall be made at the
conversion rate existing in the United States (as reported in the Wall Street
Journal) on the last business day of the calendar quarter preceding the
applicable calendar quarter. If The Wall Street Journal ceases to be published,
then the rate of exchange to be used shall be that reported in such other
business publication of national circulation in the United States as the parties
reasonably agree. Each Party shall deduct any taxes which the Party is obligated
to pay and/or withhold in its country on the payments due under this License
Agreement and pay them to the proper authorities as required by applicable laws.
Calculations of such taxes shall be consistent with Exhibit 6, but in no event
shall such calculations be inconsistent with any change in the existing law.
Therefore, it is agreed and understood that any amount paid under this License
Agreement is net of any such tax. Each Party shall maintain official receipts of
payment of any such taxes and forward these receipts to the other within sixty
(60) days and shall provide reasonable assistance to the other Party in
obtaining any credit or refund of such taxes.

         2.10 PAYMENTS' ACCOUNTS. The payments due by Bracco to EPIX according
to Section 2.3, 2.4 and 2.5 of this License Agreement shall be made by wire
transfer to EPIX using the following wiring instructions;

                           [ * ]

                           Credit to:
                           [ * ]

                           Further credit to;
                           [ * ]

         2.11 EPIX PATENTS. Within ninety (90) days of the expiration of the
last to expire claim of the Licensed Patents covering the Licensed Products, the
Parties shall meet to discuss existing patents of interest to both Parties,
including but not limited to the EPIX Patents. In the event that Bracco
expresses an interest at the meeting in acquiring a license to any patents owned
or controlled by EPIX which otherwise haven't been exclusively licensed to a
Third Party, other than the EPIX Patents, the Parties shall negotiate in good
faith commercially reasonable terms

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -8-
<PAGE>

for such a license. With respect to the EPIX Patents only, in the event EPIX
believes that one or more of the EPIX Patents covers the Licensed Products, it
shall inform Bracco in writing at least ninety (90) days prior to the meeting
and Bracco shall inform EPIX at least fifteen (15) days prior to the meeting if
it wishes to continue its license to one or more EPIX Patents. In the event that
Bracco expresses its wishes to continue the license to one or more of the EPIX
Patents, the Parties shall negotiate in good faith commercially reasonable terms
for such a license. Bracco may continue the license to one or more of the EPIX
Patents at a royalty up to and including [ * ] of Bracco Net Sales of the
Licensed Products covered by the EPIX Patents PROVIDED THAT EPIX, at its sole
discretion, may reject any offer by Bracco to pay EPIX royalties of less than [
* ] of Net Sales of the Licensed Products. However, it is understood that EPIX
shall, at the request of Bracco, be obligated to continue the license granted
herein to the Epix Patents under the same terms and conditions herein, PROVIDED
THAT Bracco is willing to pay a royalty of [ * ] as the sole payment terms and
conditions. In the event that the Parties are unable to reach an agreement on
the terms for a continuation of the license for one or more EPIX Patents
pursuant to this Section 2.11 within ninety (90) days from the date of the
meeting, then the negotiation period shall be extended for an additional ninety
(90) days, after which time any and all licenses for EPIX Patents granted
hereunder shall immediately terminate if an agreement is not reached.

                                   ARTICLE 3

                          WARRANTIES & REPRESENTATIONS

         3.1 Each Party makes the following warranties and representations to
the other Parties:

                  -        CORPORATE POWER. Each Party is a corporation duly
                           organized, validly existing and in good standing
                           under the laws of the state or country in which it is
                           organized and has all requisite power and authority
                           to enter into and perform this License Agreement and
                           the transactions contemplated hereby and to require
                           its Affiliates to abide by its terms and conditions.

                  -        DUE AUTHORIZATION. The execution, delivery and
                           performance of this License Agreement have been duly
                           authorized by all necessary corporate action on the
                           part of each Party; no consent of any Third Party is
                           needed to enter into this License Agreement.

                  -        BINDING AGREEMENT. This License Agreement is and
                           shall be a legal and valid obligation binding upon
                           each of the Parties, enforceable in accordance with
                           their respective terms.

                  -        NO CONFLICT. None of the Parties has or will enter
                           into any agreement that would interfere with the
                           rights, licenses and privileges granted under this
                           License Agreement. The execution, delivery and
                           performance of this License Agreement and the
                           consummation of the transactions contemplated hereby
                           do not and will not violate the provisions of any

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -9-
<PAGE>

                           Party's certificate of incorporation or bylaws or
                           similar type documents or the provisions of any note,
                           lease, license permit or other instrument or
                           obligation or violate any law, order, rule or
                           regulation applicable to it or conflict with any
                           agreement, instrument or understanding, oral or
                           written, to which it is a Party or by which it may be
                           bound, nor violate any material law or regulation of
                           any court, governmental body or administrative or
                           other agency having jurisdiction over it.

         3.2 EPIX WARRANTIES & REPRESENTATIONS. EPIX represents and warrants to
Bracco that:

                  (i)      it has a valid interest in the Licensed Patents and,
                           subject to the rights of the U.S. Government under 35
                           U.S.C. Sections 202, et seq., has the exclusive right
                           to sublicense such Licensed Patents to other
                           entities, including Bracco;

                  (ii)     it has not assigned, conveyed or otherwise encumbered
                           and will not do so for the life of this License
                           Agreement by any written or oral agreement or
                           otherwise any interest in the Licensed Patents or the
                           EPIX Patents in a way that would preclude, diminish
                           or limit Bracco's ability to use the Licensed Patents
                           or EPIX Patents to practice, exploit and benefit from
                           the manufacture, use or sale of Licensed Products;

                  (iii)    to its knowledge after reasonable inquiry, no person
                           has asserted or made any claim or challenge to GH's
                           right to license the Licensed Patent rights to EPIX
                           or any claim or challenge to EPIX' right to
                           sublicense the Licensed Patents;

                  (iv)     it has not transferred any rights in any of the
                           currently pending litigations or oppositions to an
                           Affiliate or another entity, that it will not apply
                           for or request from Bracco, its Affiliates, any Named
                           Entities or any other legal body any reimbursement of
                           legal fees or court costs related to any legal
                           proceeding described therein;

                  (v)      it has made a full, complete and accurate disclosure
                           of all non-privileged written material in their
                           possession and not publicly available regarding the
                           ownership, validity and enforceability of the
                           Licensed Patents to Bracco; and

                  (vi)     it has no patents or patent applications pending or
                           issued or license rights that cover the formulations
                           of the Licensed Products, nor to the best of its
                           knowledge, intermediates used in making Licensed
                           Products, methods of preparing Licensed Products or
                           methods of using Licensed Products for magnetic
                           resonance imaging the liver or central nervous system
                           other than those set forth on Exhibit 2 hereof.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -10-
<PAGE>

         3.3 BRACCO WARRANTIES & REPRESENTATIONS. Bracco represents and warrants
to EPIX that:

                  (i)      it has the full authority and necessary power of
                           attorney to act and execute the S/R Agreement on
                           behalf of its Affiliates and has the full authority
                           to terminate, in their entirety, all current actions
                           or legal proceedings instituted by all the Named
                           Entities with regard to all litigations or actions in
                           disputes with EPIX and GH, and the S/R Agreement is
                           binding and enforceable with respect to Bracco and
                           its Affiliates;

                  (ii)     to its knowledge after reasonable inquiry, the terms
                           of all sublicense agreements between Bracco and its
                           Sublicensees under Section 2.2 are in all material
                           respects not inconsistent with the terms and
                           conditions of this License Agreement; and

                  (iii)    it has not transferred any rights in any of the
                           currently pending litigations or oppositions to an
                           Affiliate or another entity, that it will not apply
                           for or request from EPIX, GH or any legal body any
                           reimbursement of legal fees or court costs related to
                           any legal proceeding described therein.

                                    ARTICLE 4

                                 CONFIDENTIALITY

         4.1 During the term of this License Agreement and for a period of five
(5) years following the expiration or earlier termination hereof, each Party
shall maintain in confidence the information received by the other Party,
including but not limited to that relating to the terms and conditions of this
License Agreement, and shall not disclose, use or grant the use of such
information of the other Party, except on a need-to-know basis to such Party's
or its Affiliates' directors, officers and employees, and such Party's
consultants and collaborators, to the extent such disclosure is reasonably
necessary in connection with such Party's activities as expressly authorized by
this License Agreement. To the extent that disclosure to any person is
authorized by this License Agreement, prior to disclosure, a Party shall advise
such person of the confidential nature of such information and not to disclose,
use or grant the use of the information of the other Party except as expressly
permitted and under this License Agreement. The confidentiality obligations
under this Section 4.1 shall not apply to the extent that a Party is required to
disclose information by applicable law, regulation or order of a governmental
agency or a court of competent jurisdiction.

         4.2 The Parties agree that press releases and other announcements to be
made by either of them in relation to this License Agreement shall be subject to
the written consent of the other Party, which consent shall not be unreasonably
withheld or delayed, except to the extent that any such press release is
required to be made by law and the consent of the other Party is not obtained
after reasonable efforts to do so. EPIX intends to issue a press release
immediately

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -11-
<PAGE>

following the execution of this License Agreement, the form and content of which
shall be in the form and in the substance similar to the one attached to this
License Agreement as Exhibit 4.

                                   ARTICLE 5

                                 INDEMNIFICATION

         5.1 With respect to each Licensed Product:

         (a) Bracco (the "Indemnifying Party") hereby agrees to save, defend and
hold EPIX and its officers, directors, consultants, agents and employees (the
"Indemnified Party") harmless from and against any and all suits, claims,
demands, liabilities, expenses and/or losses, including reasonable attorneys
fees (collectively, "Losses" or "Loss") from a Third Party claim, resulting from
or arising out of the research, development, use, import or export, manufacture,
sale, advertisement or promotion of a Licensed Product, except to the extent
such Losses result from or arise out of the inaccuracy of any representation or
warranty of EPIX set forth in this License Agreement, or the negligence or
willful misconduct of EPIX, in which case EPIX hereby agrees to save, defend and
hold Bracco and its officers, directors, consultants, agents and employees
harmless from any and all such Losses. Under these circumstances, EPIX shall be
the Indemnifying Party, Bracco and its officers, directors, consultants, agents
and employees shall be considered the Indemnified Party and the provisions of
Section 5.1(b) shall apply accordingly.

         (b) Each Indemnified Party agrees to give the Indemnifying Party prompt
written notice of any Loss or discovery of fact upon which such Indemnified
Party intends to base a request for indemnification under this Section 5.1. Each
Party shall furnish promptly to the other copies of all papers and official
documents received in respect of any Loss. With respect to any Loss relating
solely to the payment of money damages and which will not result in the
Indemnified Party becoming subject to the injunctive or other relief and as to
which the Indemnifying Party shall have acknowledged in writing the obligation
to indemnify the Indemnified Party hereunder, the Indemnifying Party shall have
the sole right to defend, settle or otherwise dispose of such Loss, on such
terms as the Indemnifying Party, in its sole discretion, shall deem appropriate.
The Indemnifying Party shall obtain the written consent of the Indemnified
Party, which shall not be unreasonably withheld or delayed, prior to ceasing to
defend, settling or otherwise disposing of any Loss if as a result thereof the
Indemnified Party would become subject to injunctive or other equitable relief
or any remedy other than the payment of money, which payment would be the
responsibility of the Indemnifying Party. The Indemnifying Party shall not be
liable for any settlement or other disposition of a Loss by the Indemnified
Party which is reached without the written consent of the Indemnifying Party.
The reasonable costs and expenses, including reasonable fees and disbursements
of counsel incurred by the Indemnified Party in connection with any Loss, shall
be reimbursed on a quarterly basis by the Indemnifying Party, without prejudice
to the Indemnifying Party's right to contest that it is ultimately not to be
obligated to indemnify the Indemnified Party.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -12-
<PAGE>

         The Indemnified Party acknowledges and agrees that in case any
potential Loss arises, it shall refrain from taking any action of any nature
whatsoever, including without limitation contacting the opposing Third Party,
the opposing Third Party's lawyer or making any public declaration on the
matter, without having previously obtained the Indemnifying Party's written
approval.

         5.2 If Bracco becomes aware that a Third Party may be infringing one or
more claims of the Licensed Patents or the EPIX Patents, Bracco shall give
prompt written notice to EPIX describing to its best information the product it
believes may be infringing such Patents and its impact on Bracco or Bracco
Affiliate sales of the Licensed Products in a particular country. In the event,
and after consultations between Bracco and EPIX, from a reasonable business and
scientific judgment, such infringement represents a serious competitive threat
to the manufacture, use and/or sale of the Licensed Products under the Licensed
Patents or the EPIX Patents, EPIX shall enforce the Licensed Patents or the EPIX
Patents.

                                   ARTICLE 6

                            DURATION AND TERMINATION

         6.1 DURATION. This License Agreement shall come into effect as of the
Effective Date and shall remain in full force and effect in each country in the
Territory until the date of expiration in such country of the last to expire of
any patent that is a Licensed Patent and that contains a Valid Claim that covers
a Licensed Product.

         6.2 TERMINATION OF THIS LICENSE AGREEMENT. This License Agreement may
be terminated by either EPIX or Bracco upon thirty (30) days notice in the event
of (i) a material breach by the other Party or (ii) bankruptcy, insolvency,
dissolution or winding up of the other Party (a "Bankruptcy Event"), except, in
the case of a petition in bankruptcy filed involuntarily against a Party, if
such petition is dismissed within sixty (60) days of the date of its filing. No
Party shall have the right to terminate this License Agreement for a material
breach without first giving written notice to the other Party setting forth in
such notice the details of the material breach and giving such other Party the
right to cure such breach within thirty (30) days (ten (10) days in the case of
a failure to make a payment on time). In the event that such other Party
believes that the breach set forth in the notice has not occurred or is not a
material breach, such other Party shall give written notice to the notifying
Party of the basis for its position within such thirty (30) day period. In the
event there is a dispute between the Parties as to whether a breach has
occurred, no Party shall have the right to terminate this License Agreement
without first following the procedures for dispute resolution set forth in
Sections 7.4, 7.5 or 7.6. In no event shall any dispute as to the infringement
of a Valid Claim of any Licensed Patent in any country or as to the validity or
enforceability of a Valid Claim of any Licensed Patent be deemed a material
breach of this License Agreement.

         6.3 In the event that Bracco or Bracco Affiliate challenges the
validity or enforceability of a Valid Claim of any Licensed Patent, then (i) all
amounts paid or payable to EPIX under Sections 2.3(a), 2.3(b), 2.3(c), 2.3(d)
and 2.4 (a) shall be immediately due, payable

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -13-

<PAGE>

and non-refundable and, if already paid shall be non-refundable, and (ii) the
royalty rate under Section 2.4(b) shall be [ * ] as of the date such challenge
was commenced.

         6.4 CONSEQUENCES OF TERMINATION OF LICENSE AGREEMENT.

         6.4.1 EXISTING OBLIGATIONS. (a) Other than for termination of this
License Agreement pursuant to Section 6.2(i), the expiration or termination of
this License Agreement for any reason shall not relieve the Parties of any
obligation that accrued prior to such expiration or termination.

               (b) Notwithstanding anything to the contrary, in case of
termination of this License Agreement for any reason whatsoever but for the
termination by EPIX pursuant to Section 6.2(i), if Bracco upon termination has
still, in part or in full, a credit towards EPIX with respect to the fees paid
by Bracco pursuant to Section 2.3(b), 2.3 (c) and Section 2.3(d), then, subject
to the terms of Section 6.3 hereof, EPIX shall refund Bracco any such fee or a
portion thereof not yet offset by Bracco as well as any excess credit royalties
pursuant to Sections 2.4 (c), 2.5 (b) and 2.5 (d).

               (c) Any refund or reimbursement of any amounts by EPIX to Bracco
under the terms of this Agreement shall be net of any taxes paid by or withheld
on behalf of EPIX at the time of the initial payment of such amounts by Bracco
to EPIX. To the extent that EPIX is able to obtain a refund of such paid or
withheld taxes, EPIX shall pay such refunded amounts to Bracco.

         6.4.2 DISPOSITION OF INVENTORY OF THE LICENSED PRODUCTS. (i) Bracco may
dispose of its inventory of the Licensed Products on hand as of the effective
date of termination, and may fill any orders for the Licensed Products accepted
prior to the effective date of termination, for a period of twenty-four (24)
months after the effective date of termination and (ii) within thirty (30) days
after disposition of such inventory and fulfillment of such orders (and in any
event within twenty-four (24) months after termination), Bracco will forward to
EPIX a final report containing the details required by Section 2.6 hereof and
pay EPIX royalties due on all Bracco Net Sales payable for such period.

         6.4.3 EFFECT OF TERMINATION BY BRACCO. In the event that this License
Agreement is terminated by Bracco pursuant to the terms hereof or EPIX has
breached this License Agreement pursuant to Section 6.2.(i), Bracco shall be
entitled to claim from EPIX in a court of competent jurisdiction all damages or
other relief which would otherwise be available to Bracco at law or in equity.

         6.4.4 EFFECT OF TERMINATION BY EPIX. In the event that this License
Agreement is terminated by EPIX pursuant to the terms hereof or Bracco has
breached this License Agreement pursuant to Section 6.2.(i), EPIX shall be
entitled to claim from Bracco in a court of competent jurisdiction all damages
or other relief which would otherwise be available to EPIX at law or in equity.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -14-
<PAGE>

         6.5 SURVIVAL. The following Sections shall survive termination of the
License Agreement: Articles 4 and 5, and Sections 6.4, 6.5, 7.1, 7.4, 7.6, 7.11,
7.12 and 7.13.

                                    ARTICLE 7

                                  MISCELLANEOUS

         7.1 NOTICES. All notices required pursuant to this License Agreement
shall be in writing, and shall be deemed to have been duly given upon the date
of receipt if delivered by hand, international overnight courier, confirmed
facsimile transmission for documents other than with respect to service of
process, or registered or certified mail (return receipt requested, postage
prepaid) to the following addresses or facsimile numbers:

                  If to EPIX:             EPIX Medical, Inc.
                                          71 Rogers Street
                                          Cambridge, MA 02142-1118
                                          Attention: Chief Executive Officer
                                          Facsimile: 617-250-6031

                  With a copy to:         Mintz, Levin, et al
                                          One Financial Center
                                          Boston, MA 02111
                                          Attention: William T. Whelan, Esq.
                                          Facsimile: 617-542-2241

                  If to Bracco:           Bracco S.p.a.
                                          Via E. Folli 50
                                          20134 Milan
                                          Attention: Group Business Development
                                          Facsimile: 011-39-02-2177-2781

                  With a copy to:         Kramer Levin Frankel & Naftalis
                                          919 Third Avenue
                                          New York, N.Y. 10022
                                          Attention: Nicholas L. Coch, Esq.
                                          Facsimile: 212- 715-8000

Either Party may change its designated address and facsimile number by notice to
the other Party in the manner provided in this Section. Service of Process by
confirmed facsimile transmission is not permitted.

         7.2 ASSIGNMENT. This License Agreement may not be assigned by either
Party without the prior written consent of the other Party, except that either
Party may assign this License Agreement to any of its Affiliates or to a
successor in connection with the merger, consolidation, or sale of all or
substantially all of its assets or that portion of its business pertaining to
the subject matter of the License Agreement, with prompt written notice to the

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -15-
<PAGE>

other Party of any such assignment. This License Agreement shall inure to the
benefit of and be binding upon the Parties and their respective lawful
successors and assignees.

         7.3 FORCE MAJEURE. Neither Party shall be held liable or responsible to
the other Party nor be deemed to have defaulted under or breached this License
Agreement for failure or delay in performing any term of this License Agreement
when such failure or delay is caused by or results from causes beyond the
reasonable control of the affected Party, including but not limited to fire,
floods, embargoes, war, acts of war (whether war is declared or not), riots,
strikes, lockouts or other labor disturbances, lawsuits, acts of God, or acts,
omissions or delays in acting by any court, governmental authority or the other
Party.

         7.4 ARBITRATION CLAUSE. In the event of a dispute between the Parties
arises out of or in connection with this License Agreement, the appropriate
officers or managers of the Parties shall meet within thirty (30) days after
notice of such dispute in a first attempt to settle through good faith
negotiations. In the event the Parties are unable to resolve such dispute, upon
the mutual consent of the Parties, such dispute may be finally settled by and
remanded to the exclusive jurisdiction of the American Arbitration Association
and a panel of three Arbitrators, appointed one by Bracco and one by EPIX, and a
third who is appointed by agreement of the first two Arbitrators or, in the
absence of such agreement, by the American Arbitration Association, who shall
act as President. The Party raising the dispute shall request the arbitration
and shall notify the other Party at the same time of the name of its own
appointed Arbitrator as provided for herein. The Party receiving such request
and notice shall within 30 (thirty) days of said notice appoint their own
Arbitrator as provided for herein and notify the other Party thereof. The
American Arbitration Association shall also proceed with the appointment of any
Arbitrator if any Party required to proceed with such an appointment shall not
have done so within the aforesaid 30 (thirty) day period. The Arbitration shall
be held in accordance with the Commercial Rules of the American Arbitration
Association and take place in New York, NY. Notwithstanding the above, without
resort to arbitration in the first instance, either Party shall have the right
to bring suit against the other Party to resolve the dispute as provided in
Section 7.6 below.

         7.5 AMENDMENT AND WAIVER. This License Agreement may be amended,
supplemented, or otherwise modified only by means of a written instrument signed
by both Parties. Any waiver of any rights or failure to act in a specific
instance shall relate only to such instance and shall not be construed as an
agreement to waive any rights or fail to act in any other instance, whether or
not similar.

         7.6 APPLICABLE LAW, JURISDICTION AND SERVICE OF PROCESS. This License
Agreement shall be governed by and construed in accordance with the laws of the
State of New York, without giving effect to the choice of law provisions
thereof. Any legal action or proceeding with respect to this License Agreement
shall be brought in the United States District Court for Southern District of
New York, if there is federal jurisdiction, or in the state courts for the State
of New York, in the Borough of New York. By execution and delivery of this
License Agreement, each of the Parties hereto accepts for itself and in respect
of its property, generally and unconditionally, the jurisdiction of the
aforesaid courts.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -16-
<PAGE>

         7.7 SEVERABILITY. In the event that any provision of this License
Agreement shall, for any reason, be held to be invalid or unenforceable in any
respect, such invalidity or unenforceability shall not affect any other
provision hereof, and the Parties shall negotiate in good faith to modify the
License Agreement to preserve their original intent.

         7.8 ENTIRE AGREEMENT. This License Agreement in conjunction with the
S/R Agreement constitutes the entire agreement between the Parties with respect
to the subject matter hereof and supersedes all prior agreements or
understandings between the Parties relating to the subject matter hereof.

         7.9 HEADINGS. The captions to the several Articles and Sections hereof
are not a part of this License Agreement, but are merely guides or labels to
assist in locating and reading the several Articles and Sections hereof.

         7.10 EXPORTS. The Parties acknowledge that the export of technical
data, materials or products is subject to the exporting Party receiving any
necessary export licenses and that the Parties cannot be responsible for any
delays attributable to export controls which are beyond the reasonable control
of either Party. EPIX and Bracco agree not to export or reexport, directly or
indirectly, any information, technical data, the direct product of such data,
samples or equipment received or generated under this License Agreement in
violation of any applicable export control laws or governmental regulations.
Bracco agrees to obtain similar covenants from their licensees, Sublicensees and
contractors with respect to the subject matter of this Section 7.10.

         7.11 COUNTERPARTS. This License Agreement may be executed in two or
more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

         7.12 INDEPENDENT CONTRACTORS; NEGATION OF PARTNERSHIP. The relationship
of EPIX and Bracco established by this License Agreement is that of independent
contractors, and nothing contained in this License Agreement shall be construed
to give either Party the power to direct or control the day-to-day activities of
the other, or allow one Party to create or assume an obligation on behalf of the
other Party for any purpose whatsoever. This License Agreement is not intended
to create a partnership between EPIX and Bracco for United States federal income
tax purposes for any state or local jurisdiction in the United States, or for
any country other than the United States. Therefore, there is no requirement in
the United States to file Form 1065, United States Partnership Return of Income,
or any similar state or local income tax return in any political subdivision, of
the United States, or any similar tax document in any country other than the
United States in regard to the contractual relationship described in this
License Agreement.

         7.13 AMBIGUITIES. The Parties acknowledge and agree that: (i) each
Party reviewed and negotiated the terms and provisions of this License Agreement
and have contributed to its revision; (ii) the rule of construction to the
effect that any ambiguities are resolved against the drafting Party shall not be
employed in the interpretation of this License Agreement; and (iii) the terms
and provisions of this License Agreement shall be construed fairly as to all
Parties hereto and not in favor of or against any Party, regardless of which
Party was generally responsible for the preparation of this License Agreements.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -17-
<PAGE>

         IN WITNESS WHEREOF, the undersigned have duly executed and delivered
this License Agreement as of the date first above written.

BRACCO IMAGING S.P.A.                      EPIX MEDICAL, INC.

By: /s/ Diana Bracco                       By: /s/ Michael D. Webb
    ---------------------------                ------------------------------
Title: Chairman                            Title: CEO
       ------------------------                   ---------------------------
Date: September 25, 2001                   Date: September 24, 2001
      ------------------------                   ---------------------------

Exhibits Attached:

Exhibit 1: List of Current Bracco Affiliates and Current Sublicensees
Exhibit 2: List of Patents
Exhibit 3: Calculation of Offset to Royalties Pursuant to Section 2.5(b)
Exhibit 4: Press Release
Exhibit 5: List of Countries having Issued Licensed Patents
Exhibit 6: Accountants' Letter regarding tax calculations

THE FOREGOING EXHIBITS HAVE BEEN OMITTED AND WILL BE FURNISHED SUPPLEMENTALLY TO
THE COMMISSION UPON REQUEST.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                      -18-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]